Concurrently, Eusa has divested its recombinant L-asparaginase therapeutic research program for acute lymphoblastic leukemia to the Alize Pharma Group. EUSA acquired both the antibody business and oncology program as part of its 2007 acquisition of OPi.
Eusa’s antibody research business is based in Dardilly, France, and consists of a team of R&D scientists, laboratories and a library of approximately 600 murine antibodies, of which a high proportion are currently characterized.
The divestment agreement for Eusa’s recombinant L-asparaginase therapeutic research program includes an option for the company to license back any resulting product. This provides Eusa with access to a potential future product that has an ideal fit with the company’s oncology focus.